Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).
复制标题
DOI：
10.1186/1471-244x-13-214
复制
发表时间：
2013-08-22
期刊：
影响因子：
4.4
通讯作者：
Shim JC
中科院分区：
文献类型：
--
作者：
Kelly DL;Wehring HJ;Earl AK;Sullivan KM;Dickerson FB;Feldman S;McMahon RP;Buchanan RW;Warfel D;Keller WR;Fischer BA;Shim JC
催乳素升高发生在抗精神病药物治疗的人群中，女性的催乳素水平通常比男性高得多。已知高泌乳素血症可引起女性闭经、月经过少、泌乳过多和男性乳房发育，也与性功能障碍和骨质流失有关。这些副作用增加了抗精神病药物不依从性和自杀的风险，并在精神分裂症妇女的长期管理中造成了重大问题。在这篇手稿中，我们回顾催乳素的文献，其生理学，血浆水平，副作用和治疗策略。我们还提出了一个正在进行的临床试验，以治疗症状性高泌乳素血症的绝经前妇女精神分裂症的基本原理和协议。需要更多的关注和关注来解决这些显著的副作用，并帮助该领域更好地个性化治疗女性精神分裂症。
Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.